Tumor Immunity ——卓越一班二组——. Tumor Immunity ——卓越一班二组——

Slides:

Advertisements

Similar presentations

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Advertisements

Unmet Needs Today and Treatment Goals of the Future: The Role of Immuno-Oncology Prof. Karim Vermaelen, UZ Gent on behalf of Sacha Rothschild MD PhD, University.

The principle of immunotherapy using dendritic cell vaccine: (1) monocytes are isolated from the peripheral blood and (2,3) manipulated in experimental.

Tumor Immunology (I): Cancer Immunosurveillance & Immunoediting Masoud H. Manjili Department of Microbiology & Immunology Goodwin Research Building-286.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Host Defense Against Tumors (Tumor Immunity)

Cancer immunotherapy: an update

Meredith Baker, MD PI: Bo Lu, MD – Radiation Oncology May 29th, 2014

YOUR CANCER TREATMENT: WHAT TO EXPECT FROM THE LATEST ADVANCEMENTS MIRIAM J. ATKINS, M.D.

Cancer immunotherapy: an update

Bijoy Telivala, MD Advances in Immunotherapy Bijoy Telivala, MD

Wolfram C. M. Dempke SaWo Oncology Ltd May 13, 2017

Immunological tolerance and immune regulation -- 1

HOST DEFENCE AGAINST TUMORS:

Metastatic Head Neck Cancer and Immunotherapy

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Atezolizumab Drugbank ID : DB11595.

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Cancer and the Immune System

chimeric antigen receptor T-cell therapy for ALL

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Tumor Immunity: Exploring the Role of a Checkpoint

Avoiding Immune Detection

Prot eins Immune Checkpoint. CONTENTS Page 3 Immune System Page 7 Cancer and Immune Response Page 9 Immuno-Oncology Page 12 Immune Checkpoint Proteins.

Group 6 Melinda Bachini, Thelma Brown, Jean Di Carlo-Wagner, Bob Riter, Chris Kinsinger, Keith Chan, Penny Blaisdell IMMUNOTHERAPY.

Immunotherapy of hepatocellular carcinoma

The Immune System. The Immune System Adaptive Immune Response.

Immunotherapy for lymphoma: The time is now

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Discussion Outline Cells of the Immune System.

The yin and yang of evasion and immune activation in HCC

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Advances in Specific Immunotherapy for Prostate Cancer

Dr. Gülderen Yanıkkaya Demirel

Figure 3 Altered adaptive immune functions after sepsis

Figure 2 Neoantigen presentation in the tumour microenvironment

Converting Cold into Hot Tumors by Combining Immunotherapies

Research Techniques Made Simple: CAR T-Cell Therapy

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Hiding in Plain Sight: How Cancer Evades the Immune System

Nat. Rev. Rheumatol. doi: /nrrheum

Targets for immunotherapy of liver cancer

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Site of action of checkpoint inhibitors and agonists being

The yin and yang of evasion and immune activation in HCC

Robert J Korst, MD, Ronald G Crystal, MD

Volume 25, Issue 1, Pages (January 2014)

Nat. Rev. Endocrinol. doi: /nrendo

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Nat. Rev. Urol. doi: /nrurol

Turning Tumors into Vaccines: Co-opting the Innate Immune System

Tumor immunology.

Figure 1 Mechanisms of action of immunotherapy modalities

Nat. Rev. Urol. doi: /nrurol

Michele De Palma, Rakesh K. Jain Immunity

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Padmanee Sharma, James P. Allison Cell

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Immunological effects of anticancer therapy.

Presentation transcript:

Tumor Immunity ——卓越一班二组——

Introduction We may forget the past But the past won't forget us

Tumor Antigen A B TSA: Tumor-specific antigen TAA: Tumor-associated antigen

Tumor Antigen CEA --Carcinoembryonic antigen --A kind of TAA --It can be used as a tumor marker in clinical tests

Elimination --The innate and adaptive immune system together detect and destroy early tumors --Before tumors become clinically visible.

Escape CTLA-4: --Cytotoxic T lymphocyte-associated antigen-4 --Combine with B7 --Participate in immunosuppression PD-L1(CD274): --Programmed death-ligand 1 --Combine with PD-1 --Participate in immunosuppression

Immunoediting Elimination Equilibrium Escape Resist immune recognition Induce immune suppression Intimate immunity Adaptive immunity

Treatment DC-CIK --A kind of adoptive immunotherapy --Is obsolete

Treatment CAR-T --CAR: chimeric antibody receptor --Is sufficient to promote T cell proliferation, CK production and target cell cytolysis

Treatment PD-1--PD-L1/2 CTLA-4/CD28--B7

Tecentriq --The first and only FDA-approved anti-PDL1 cancer immuotherapy --Treat patients with locally advanced or metatatic urothelial carcinoma(mUC)

C Summary Introduction Tumor antigen Imunoediting Treatment 01 02 03 04 Treatment

Discussion “Antioxidant can lead cancer, and ROS during radiotherapy can kill cancer cells.” “But, if we use the natural ROS which is produced by our own bodies, the side-effect will no longer be considered. ” James Watson

How many years must a patient fight Before he is free from pills How many pains must a patient stand Before he finally heals How many torments must a patient suffer Before the tumor is removed forever The answer my friends, is lying in our hands The answer is lying in our hands How many years will we wait Before scientists figure out the method To cure cancer which is efficient How many mistakes will we meet Till we eventually find out the treatment For every cancer of each patient The answer my friends, is lying in our hands The answer is lying in our hands ---- By Group 2

Thank You